Cite
HARVARD Citation
Yan, S. et al. (n.d.). 340TiPA multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection. Annals of oncology. p. . [Online].